Pharma major Lupin said it has agreed to sell its Japanese injectables business to a wholly owned subsidiary of Neopharma group, the UAE's largest pharmaceutical manufacturer headquartered in Abu Dhabi. \n\n\n\nLupin has agreed to sell all the issued and outstanding share capital in its unit Kyowa Criticare Co. Ltd to neo ALA Co. Ltd, a unit of Neopharma.\n\n\n\nThe injectables plant and associated facilities are based out of Atsugi, Japan and has been engaged in sales and contract manufacturing of injectable product.\n\n\n\nThe transaction does not involve or affect the other operations of Lupin's Japanese subsidiary Kyowa, namely research, manufacturing, marketing and distribution of oral solids and other dosage forms in Japan. \n\n\n\nLupin said it wants to focus on its drugs business in Japan.\n\n\n\n"The divestiture of our injectables business in Japan is a step towards streamlining our Japan operations and bringing sharper focus on building a hybrid (brand\/ generics) pharma model in Japan," said Fabrice Egros, President Lupin APAC and Representative Director\u2014 Kyowa .\n\n\n\nSuresh Nandiraju, Chief Operating Officer of Neopharma, said the acquisition is synergetic to his firm and will strengthen its product offerings in the Japanese market.\n\n\n\nLupin is one of the world's top generics manufacturers and is also present in branded formulations, biotechnology products and ingredient manufacturing. \n\n\n\nThe Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment. \n\n\n\nLupin is the 8th largest generics pharmaceutical company by revenues and the 3rd largest pharmaceutical player in the US by prescriptions.